Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease

Jermaine Goveia1, Peter Stapor1, Peter Carmeliet2

  • 1Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven, Belgium Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center VIB, Leuven, Belgium.

Insights

Targeting endothelial cell (EC) metabolism offers a novel therapeutic strategy for diseases linked to abnormal blood vessel growth and EC dysfunction. This approach aims to reverse dysfunction and inhibit pathological angiogenesis by addressing metabolic alterations.

Area of Science:

  • Vascular Biology
  • Metabolic Research
  • Pathology

Background:

  • Endothelial cells (ECs) orchestrate blood vessel function.
  • Pathological angiogenesis and EC dysfunction are hallmarks of various diseases.
  • Current therapies for these conditions have limited efficacy.

Purpose of the Study:

  • To review recent advancements in understanding EC-specific metabolic alterations in disease.
  • To discuss potential metabolic targets for therapeutic intervention.
  • To explore strategies for reversing EC dysfunction and inhibiting pathological angiogenesis.

Main Methods:

  • Literature review of recent scientific findings.
  • Analysis of EC-specific metabolic changes in disease contexts.
  • Identification and discussion of potential therapeutic targets and strategies.

Main Results:

  • Pathological angiogenesis and EC dysfunction are associated with EC-specific metabolic alterations.
  • Targeting EC metabolism is an emerging therapeutic strategy.
  • Metabolic interventions hold promise for treating cancer and cardiovascular diseases.

Conclusions:

  • Understanding EC metabolism is crucial for developing effective treatments.
  • Modulating EC metabolism can potentially reverse disease-associated dysfunction.
  • Targeting EC metabolism represents a promising frontier in vascular disease therapy.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
611
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.8K